Found vs Henry Meds vs SkinnyRx (2026)

On tirzepatide, the order is Found ($289) → SkinnyRx↗ ($299) → Henry Meds↗ ($349) — gaps of $10 and then $50 a month, a $720 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

Found: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

SkinnyRx: the record, condensed

Start with the load-bearing figure: $299 a month, all-in, is what SkinnyRx charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #7 of 17 verified programs, with the floor $84/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.

SkinnyRx’s semaglutide program bills $199 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $199 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #11 of 20 in the verified semaglutide index — $66/month above the floor (Oak Longevity, $133) — and sits $150 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,388.

Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗

Henry Meds: the record, condensed

On tirzepatide, the number that matters at Henry Meds is $349 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

Found holds the low ground at $289 — dose-flat, so that figure is a ceiling with no membership attached. SkinnyRx follows at $299 (+$10/mo, $120/yr). Henry Meds tops the trio at $349 (+$60/mo over the leader, $720/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles the order: Henry Meds $179 → SkinnyRx $199 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: Found ($289); cheapest 12-month path: Found ($3,468); cheapest semaglutide of the three: Henry Meds ($179).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Found vs SkinnyRx · Found vs Henry Meds · SkinnyRx vs Henry Meds.

§ Structure, three ways

Everything besides the three prices

Memberships: Found none; SkinnyRx none; Henry Meds none. Structures: Found dose-flat; SkinnyRx dose-flat; Henry Meds dose-flat. Pharmacies: Found not named; SkinnyRx not named; Henry Meds not named. States: Found — most states; SkinnyRx — not published; Henry Meds — most states. Exit terms: Found — membership recurs; prepaid terms are paid up front; SkinnyRx — no membership on compounded programs; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Found third-party reported (2026-08-05); SkinnyRx source-verified (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: Henry Meds $537 vs SkinnyRx $597 vs Found $867 6 mo: Henry Meds $1,074 vs SkinnyRx $1,194 vs Found $1,734 12 mo: Henry Meds $2,148 vs SkinnyRx $2,388 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

Found: $3,468/yr monthly-billed; SkinnyRx: $3,588/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,440 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Henry Meds first unless it names its edge: at $349 it carries a $60/month premium over the floor of this trio — $720 a year, about 2.5 extra months of therapy at Found’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate SkinnyRx’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $10/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Found at $289, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: Found $289 → SkinnyRx $299 → Henry Meds $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Found $867, SkinnyRx $897, Henry Meds $1,047; 6 months — Found $1,734, SkinnyRx $1,794, Henry Meds $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Found 3/5, SkinnyRx 4/5, Henry Meds 3/5. SkinnyRx discloses the most and Found the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from Found and make the other two argue upward. SkinnyRx’s case is its structure; Henry Meds’s case must be worth $720 a year in named features — the honest unit being months of medication (2.5 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.